Parabilis Medicines, Inc. 4

Guy Levy–affiliated Soleus funds bought 500,000 Parabilis Medicines (PBLS) common shares at $20.00 per share (~$10 million total) and converted 527,070 Series F Preferred shares into common stock in connection with the IPO.

On June 11, 2026, investment vehicles affiliated with Guy Levy reported significant insider purchases of Parabilis Medicines, Inc. common stock in connection with the company’s IPO, along with an automatic conversion of preferred shares. Soleus-affiliated funds acquired 375,000 shares of common stock at $20.00 per share for approximately $7.5 million, increasing their indirect ownership in one account to 1,027,000 shares, and separately acquired 125,000 shares at $20.00 per share for about $2.5 million, raising another indirect account to 652,000 shares. In addition, 527,070 shares of Series F Preferred Stock automatically converted into 527,070 shares of common stock immediately prior to the IPO at an effective reference price of $9.48 per share, moving these shares into indirect common stock ownership and eliminating the preferred position; the resulting common holdings from this conversion are valued at roughly $4.99 million at $9.48 per share (or about $10.54 million at the IPO price). These securities are held by Soleus Private Equity Fund III, L.P. and Soleus Capital Master Fund, L.P., with complex upstream general partner and investment manager entities, and Mr. Levy and the related Soleus entities expressly disclaim beneficial ownership except to the extent of their pecuniary interests.

Filing Facts

CIK

1657677

Ticker

PBLS

Form

4

Source Type

sec

Accession

0001213900-26-072928

Alert Tier

8

ATTN Analysis